1419P Radiobiological parameters for the assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

The lack of robust radiobiological data hampers the further optimization of emerging 177Lu-PSMA-directed radioligand therapy (RLT). This study aims to explore several conventional radiobiological parameters in the assessment of outcomes in tumor and normal organs at risk (OARs) for castration-resistant prostate cancer (CRPC) patients.